

Deutsches Krebsforschungszentrum
Alonso et al.

6.10.2000
DK61769US IB/UK/cp

5

Claims

1. Method of diagnosis of the existence and/or the pathological developmental stage and/or the grade of malignancy of carcinomas and/or sarcomas in mammals characterized by the preparation of a body sample of said mammals and the determination of the overexpression of the protein Nup88 in said sample.
2. Method of claim 1 characterized in that the mammal is a human being.
- 15 3. Method of claim 1 characterized in that the determination of the overexpression is based on the use of a protein binding molecule binding to Nup88.
4. Method of claim 1 characterized in that the determination of the overexpression is based on the use of a nucleic acid binding molecule binding to the transcript of Nup88.
- 20 5. Method of claim 3 characterized in that the protein binding molecule is a monoclonal antibody directed against Nup88.
- 25 6. Method of claim 5 characterized in that the monoclonal antibody is 149/1/1 (DSM ACC 2457).
7. Method of claim 3 characterized in that the protein binding molecule is a chimeric protein that exhibits homology to antibodies of mammals.

- 25 -

8. Method of claim 7 characterized in that at least one CDR region of said monoclonal antibody is virtually identical with the corresponding counterpart of 149/1/1 (DSM ACC 2457).

5 9. Diagnostic kit for carrying out the method of claim 1 comprising a protein binding molecule binding to Nup88.

10. Diagnostic kit for carrying out the method of claim 1 comprising a nucleic acid binding molecule binding to the transcript of Nup88.

10

11. Kit of claim 9 further comprising Nup88 or an antigenic part thereof for control reactions.

12. Monoclonal antibody as deposited under DSM ACC 2457.

15

ADD
A1